Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 7/20 | 0.53 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 2/20 | 0.49 |
| ▸ | PTAFR | P25105 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8464891 | 1.00 | TBXAS1 (0.53) | TBXAS1CYP2A6TDP1L3MBTL1HRH1 | |
| SCHEMBL7384270 | 0.97 | TBXAS1 (0.55) | TBXAS1CYP2A6TDP1L3MBTL1HRH1 | |
| SCHEMBL7549229 | 0.97 | TBXAS1 (0.55) | TBXAS1CYP2A6TDP1L3MBTL1HRH1 | |
| SCHEMBL3923399 | 0.92 | CYP2A6 (0.59) | TBXAS1CYP2A6TDP1L3MBTL1HRH1 | |
| SCHEMBL5016747 | 0.88 | CHRNA7 (0.57) | TBXAS1CYP2A6TDP1L3MBTL1HRH1 | |
| SCHEMBL10696169 | 0.88 | TBXAS1 (0.49) | TBXAS1CYP2A6TDP1L3MBTL1HRH1 | |
| SCHEMBL8593616 | 0.86 | MMP12 (0.55) | TBXAS1CYP2A6PTAFRCHRNA7LMNA | |
| SCHEMBL10695136 | 0.85 | PTAFR (0.51) | TBXAS1PTAFR | |
| SCHEMBL2921490 | 0.85 | TRPA1 (0.53) | — | |
| SCHEMBL27339729 | 0.84 | CYP2A6 (0.47) | TBXAS1CYP2A6TDP1L3MBTL1HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1086386-C | Multi-drug resistance modifiers | VERTEX PHARMA (US) | 2002-06-19 | — | — | CN | disclosed |
| EP-0584223-B1 | NOVEL IMMUNOSUPPRESSIVE COMPOUNDS | VERTEX PHARMA (US) | 1999-08-11 | — | — | EP | disclosed |
| US-5723459-A | IMMUNOSUPPRESSANTS FOR MULTIDRUG RESISTANCE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1998-03-03 | — | — | US | disclosed |
| US-5620971-A | Biologically active acylated amino acid derivatives | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1997-04-15 | — | — | US | disclosed |
| EP-0662958-A1 | 1-(2-OXO-ACETYL)-PIPERIDINE-2-CARBOXYLIC ACID DERIVATIVES AS MULTI-DRUG-RESISTENT CANCER CELL SENSITIZERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1995-07-19 | — | — | EP | disclosed |
| CN-1088577-A | Novel multi-drug resistance modifiers | VERTEX PHARMA (US) | 1994-06-29 | — | — | CN | disclosed |
| WO-1994007858-A1 | 1-(2-OXO-ACETYL)-PIPERIDINE-2-CARBOXYLIC ACID DERIVATIVES AS MULTI-DRUG-RESISTENT CANCER CELL SENSITIZERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1994-04-14 | — | — | WO | disclosed |
| EP-0584223-A1 | NOVEL IMMUNOSUPPRESSIVE COMPOUNDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1994-03-02 | — | — | EP | disclosed |
| WO-1992019593-A1 | NOVEL IMMUNOSUPPRESSIVE COMPOUNDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1992-11-12 | — | — | WO | disclosed |